Bright Peak Presents New Data at AACR: BPT567 A First-in-Class Multifunctional PD1-IL18 Immunocytokine
– Designed to deliver coordinated blockade of PD-1/PD-L1 pathway with targeted, enhanced IL-18 signaling to critical antitumor effector cells – – T cells co-expressing PD-1 and IL-18 receptors are highly enriched in the tumor microenvironment (TME) versus peripheral blood, providing rationale for tumor-selective targeting with BPT567 – – Marked expansion